New and effective therapies are sorely needed for the treatment of Alzheimer’s Dementia. When the FDA approved the first new drug for Alzheimer’s Dementia in 18 years though, it was met with unprecedented criticism from experts in the fields of neurology and gerontology. So, what’s the deal with aducanumab? Join us and panelists Ashley Campbell, Pharm.D., BCPS and Shannon Rice, Pharm.D., BCGP, as we discuss the data behind aducanumab’s efficacy, safety, and whether or not this medication should be used as a standard in clinical practice.

Follow-up points from this podcast:

1. Citation on the minimum clinically important difference in the Clinical Dementia Rating Scale – Sum of Boxes: Andrews JS, Desai U, Kirson NY, Zichlin ML, Ball DE, Matthews BR. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer's disease clinical trials. Alzheimers Dement (N Y). 2019;5(1):354-363.
2. The MRI monitoring frequency implemented in the ENGAGE and EMERGE Trials was at baseline, 3 months, 5 months, 7 months, and then every 3 months thereafter until study completion.

Interested in joining the Orange County Society of Health-System Pharmacists? Join us at https://ocshp.com/join-us/ ! Interested in appearing on the podcast? Let us know by emailing leadership@ocshp.com.